ARN-75039

Phase 2Small molecule

AArisan Therapeutics, Inc.

ARN-75039 is one of 4 small molecule programs targeting Lassa fever. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lassa FeverActive, not recruiting

Lassa FeverPhase 2

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Lassa Fever

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

2 2

Virazole

CConrado Roberto Hoffmann Filho

Phase 2

4 3

Avigan

AAppili Therapeutics Inc.

Phase 2

2 4

ARN-75039

AArisan Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adult1 trial

A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions

Completed·AArisan Therapeutics, Inc.·Phase 1·NCT06911242·16 enrolled

Adult Subject1 trial

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

Completed·AArisan Therapeutics, Inc.·Phase 1·NCT05735249·94 enrolled

Lassa fever1 trial

A Phase 2 Study to Evaluate Safety, Tolerability, And Virologic Efficacy of ARN-75039 For the Treatment of Lassa Fever in West Africa

Suspended·AArisan Therapeutics, Inc.·Phase 2·NCT07419373·135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ARN-75039. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARN-75039 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARN-75039. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arisan Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AArisan Therapeutics, Inc.

ARN-75039

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adult1 trial

Adult Subject1 trial

Lassa fever1 trial

References

Drug Info

Quick Facts

Related News